Following up on our previous work demonstrating that up-regulation of NEK2 leads to therapy resistance and inferior survival in patients with MM [14], we decided to explore whether NEK2 might be involved in the mechanism by which ALDH1A1 promotes drug resistance in myeloma. The gene discussed is ALDH1A1; the disease is plasma cell myeloma.